Pasanen MK - Search Results

1

Different effects of SLCO1B1 polymorphism on the pharmacokinetics of atorvastatin and rosuvastatin.

Pasanen MK, Fredrikson H, Neuvonen PJ, Niemi M. Pasanen MK, et al. Clin Pharmacol Ther. 2007 Dec;82(6):726-33. doi: 10.1038/sj.clpt.6100220. Epub 2007 May 2. Clin Pharmacol Ther. 2007. PMID: 17473846

2

Effect of SLCO1B1 polymorphism on the plasma concentrations of bile acids and bile acid synthesis marker in humans.

Xiang X, Han Y, Neuvonen M, Pasanen MK, Kalliokoski A, Backman JT, Laitila J, Neuvonen PJ, Niemi M. Xiang X, et al. Among authors: pasanen mk. Pharmacogenet Genomics. 2009 Jun;19(6):447-57. doi: 10.1097/FPC.0b013e32832bcf7b. Pharmacogenet Genomics. 2009. PMID: 19387419

3

Global analysis of genetic variation in SLCO1B1.

Pasanen MK, Neuvonen PJ, Niemi M. Pasanen MK, et al. Pharmacogenomics. 2008 Jan;9(1):19-33. doi: 10.2217/14622416.9.1.19. Pharmacogenomics. 2008. PMID: 18154446

4

Polymorphism of the hepatic influx transporter organic anion transporting polypeptide 1B1 is associated with increased cholesterol synthesis rate.

Pasanen MK, Miettinen TA, Gylling H, Neuvonen PJ, Niemi M. Pasanen MK, et al. Pharmacogenet Genomics. 2008 Oct;18(10):921-6. doi: 10.1097/FPC.0b013e32830c1b5f. Pharmacogenet Genomics. 2008. PMID: 18794729

5

Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake.

Niemi M, Pasanen MK, Neuvonen PJ. Niemi M, et al. Among authors: pasanen mk. Pharmacol Rev. 2011 Mar;63(1):157-81. doi: 10.1124/pr.110.002857. Epub 2011 Jan 18. Pharmacol Rev. 2011. PMID: 21245207 Review.

6

Different effects of the ABCG2 c.421C>A SNP on the pharmacokinetics of fluvastatin, pravastatin and simvastatin.

Keskitalo JE, Pasanen MK, Neuvonen PJ, Niemi M. Keskitalo JE, et al. Among authors: pasanen mk. Pharmacogenomics. 2009 Oct;10(10):1617-24. doi: 10.2217/pgs.09.85. Pharmacogenomics. 2009. PMID: 19842935

7

SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid.

Pasanen MK, Neuvonen M, Neuvonen PJ, Niemi M. Pasanen MK, et al. Pharmacogenet Genomics. 2006 Dec;16(12):873-9. doi: 10.1097/01.fpc.0000230416.82349.90. Pharmacogenet Genomics. 2006. PMID: 17108811

8

Association of genetic polymorphism in ABCC2 with hepatic multidrug resistance-associated protein 2 expression and pravastatin pharmacokinetics.

Niemi M, Arnold KA, Backman JT, Pasanen MK, Gödtel-Armbrust U, Wojnowski L, Zanger UM, Neuvonen PJ, Eichelbaum M, Kivistö KT, Lang T. Niemi M, et al. Among authors: pasanen mk. Pharmacogenet Genomics. 2006 Nov;16(11):801-8. doi: 10.1097/01.fpc.0000230422.50962.91. Pharmacogenet Genomics. 2006. PMID: 17047488

9

SLCO1B1 polymorphism and sex affect the pharmacokinetics of pravastatin but not fluvastatin.

Niemi M, Pasanen MK, Neuvonen PJ. Niemi M, et al. Among authors: pasanen mk. Clin Pharmacol Ther. 2006 Oct;80(4):356-66. doi: 10.1016/j.clpt.2006.06.010. Clin Pharmacol Ther. 2006. PMID: 17015053 Clinical Trial.

10

Itraconazole, gemfibrozil and their combination markedly raise the plasma concentrations of loperamide.

Niemi M, Tornio A, Pasanen MK, Fredrikson H, Neuvonen PJ, Backman JT. Niemi M, et al. Among authors: pasanen mk. Eur J Clin Pharmacol. 2006 Jun;62(6):463-72. doi: 10.1007/s00228-006-0133-z. Epub 2006 Apr 27. Eur J Clin Pharmacol. 2006. PMID: 16758263 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results